Trial Profile

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
Indications Multiple myeloma; Plasmacytoma
Focus Therapeutic Use
Acronyms Perseus

03 Jun 2025 Results presented in a Janssen-Cilag Media Release.
03 Jun 2025 According to a Johnson & Johnson media release, company announced findings highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
03 Jun 2025 Results published in the Johnson & Johnson media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com